Here’s how I see the interim analysis in ARDS going down:
The speed of enrollment lends itself to a majority of the 90 patients being in the moderate ARDS category (<200 mmHg). This means less mortality in the placebo group. There will be a decreased mortality rate using the cells vs. placebo, but it will not be statistically significant. In severe ARDS (<100 mmHg), you will see a more significant difference vs. placebo. However, due to the low number of severe patients enrolled, it will also not be statistically significant. I expect the trial to be able to continue to the next interim readout at 135 patients, or 45%.
Educated thoughts?
COVID ARDS interim analysis
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |